Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
This action will combine every 3 shares into 1 share, reducing outstanding common stock.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split on August 18, 2025.
Nasdaq Compliance
The reverse split is part of a plan to meet Nasdaq's minimum bid price requirement.
CEO Statement
Richard Paolone emphasized the importance of the Nasdaq listing for shareholder value.
- The reverse split affects the outstanding common stock from approximately 4.77 million shares to 1.59 million shares.
- Fractional shares will be converted to cash for stockholders.
- The visibility and credibility of a Nasdaq listing are crucial for the company's value enhancement.
The reverse stock split by Entero Therapeutics, Inc. is a strategic move to maintain its Nasdaq listing, highlighting the company's focus on shareholder value and compliance with market requirements.